Fig. 6
From: Therapeutic potential of TAS-115 via c-MET and PDGFRα signal inhibition for synovial sarcoma
TAS-115 strongly abrogates the growth of Yamato-SS and SYO-1 xenograft tumours. a The appearance of resected Yamato-SS tumours at the end of the experiments. b Mice bearing Yamato-SS xenografts were treated with 50 or 200 mg/kg of TAS-115, or control. Bars represent the SE. * p < 0.05. c Immunohistological analysis of PCNA (× 200). Scale bars, 100 μm. d PCNA-positive rate of each treatment group. Bars represent the SD. * p < 0.05. e The appearance of resected SYO-1 tumours at the end of the experiments. f Mice bearing SYO-1 xenografts were treated with 50 or 200 mg/kg of TAS-115, or control. Bars represent the SE. * p < 0.05. g Immunohistological analysis of PCNA (× 200). Scale bars, 100 μm. h PCNA-positive rate of each treatment group. Bars represent the SD. * p < 0.05